Cancer NetworkOriginal article
<![CDATA[Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC]]>
Phase 3MixedFirmonertinibNegative
AI Analysis
Summary
The phase 3 FURVENT trial for firmonertinib missed its primary PFS endpoint in first-line EGFR exon 20 insertion-mutant NSCLC, although the drug demonstrated an objective response rate benefit.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Missed primary endpoint (PFS) but showed objective response rate benefit
Importance:6/10
Sentiment:
-0.40
Phase 3NSCLCEGFR mutationendpoint missoncology
Related Companies
Read the original article
Published by Cancer Network on October 6, 2026 4:00 PM